Article Details

DelveInsight Evaluates a Robust Multiple Sclerosis Clinical Trial as 100+ Influential Pharma ...

Retrieved on: 2023-09-11 23:18:10

Tags for this article:

Click the tags to see associated articles and topics

DelveInsight Evaluates a Robust Multiple Sclerosis Clinical Trial as 100+ Influential Pharma .... View article details on HISWAI: https://www.digitaljournal.com/pr/news/getnews/delveinsight-evaluates-a-robust-multiple-sclerosis-clinical-trial-as-100-influential-pharma-companies-to-set-foot-in-the-7mm

Excerpt

... Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, ...

Article found on: www.digitaljournal.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up